Construction of an EMT-related LncRNA Prognostic Signature for Lung Adenocarcinoma and Functional Verification of Its Hub Gene LINC01615

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Nov 7

PMID 37934255

Authors

Yifan Shan

Tingting Xia

Weijia Xie

Weiping Wan

Na Wu

Zhiquan Yuan

Qin Hu

Zheng Chen

Chengying Li

Long Wu

Wenhui Wu

Tongjian Cai

Ying Xiang

Li Bai

Yafei Li

Affiliations

Soon will be listed here.

Abstract

Background: The epithelial-mesenchymal transition (EMT) plays a vital role in the progression of lung adenocarcinoma (LUAD). Long non-coding RNAs (lncRNAs) participate in the EMT process as an important regulatory factor and have the potential to serve as prognostic biomarkers. We aimed to construct a novel lncRNA prognostic signature for LUAD based on EMT-related lncRNAs, identify EMT-related hub lncRNA, and investigate its biological functions.

Methods: RNA-seq data, clinical and survival information were obtained from The Cancer Genome Atlas database. The EMT-related lncRNA prognostic signature (EMTscore) was constructed using the Least Absolute Shrinkage and Selection Operator Cox regression analysis. The efficiency of EMTscore in predicting the prognosis of LUAD was evaluated through the area under the time-dependent receiver operating characteristic (ROC) curves. The hub lncRNA of the prognostic signature was selected using a co-expression network map, and its effects on cell proliferation and metastasis were explored by in vitro experiments.

Results: We constructed a prognostic signature (EMTscore) containing 8 tumor-high expressed lncRNAs. The EMTscore performed well in predicting overall survival rates with AUC values of 0.708 at 5 years in the training set. EMTscore could independently predict the survival of LUAD, with HR = 4.011 (95% CI 2.430-6.622) in the multivariate Cox regression. Importantly, we identified LINC01615 as the hub lncRNA in the EMTscore and revealed that LINC01615 enhanced the proliferation, migration, and EMT of lung cancer cells.

Conclusions: A new EMT-related lncRNA prognostic signature named EMTscore was developed, and LINC01615 was identified as the hub lncRNA of EMTscore. The hub lncRNA LINC01615 had an oncogenic biological function in LUAD.

References

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

Cao Z, Wang Z, Leng P . Aberrant N-cadherin expression in cancer. Biomed Pharmacother. 2019; 118:109320. DOI: 10.1016/j.biopha.2019.109320. View

Chen Y, Li C, Pan Y, Han S, Feng B, Gao Y . The Emerging Role and Promise of Long Noncoding RNAs in Lung Cancer Treatment. Cell Physiol Biochem. 2016; 38(6):2194-206. DOI: 10.1159/000445575. View

Chen Z, Hu Z, Sui Q, Huang Y, Zhao M, Li M . LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma. Int J Biol Sci. 2022; 18(2):522-535. PMC: 8741836. DOI: 10.7150/ijbs.67556. View

Ettinger D, Akerley W, Borghaei H, Chang A, Cheney R, Chirieac L . Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013; 11(6):645-53. DOI: 10.6004/jnccn.2013.0084. View

Grelet S, Link L, Howley B, Obellianne C, Palanisamy V, Gangaraju V . A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol. 2017; 19(9):1105-1115. PMC: 5578890. DOI: 10.1038/ncb3595. View

Gu Z, Liu W . The LncRNA AL161431.1 targets miR-1252-5p and facilitates cellular proliferation and migration via MAPK signaling in endometrial carcinoma. Eur Rev Med Pharmacol Sci. 2020; 24(5):2294-2302. DOI: 10.26355/eurrev_202003_20495. View

Hashemi M, Moosavi M, Maghareh Abed H, Dehghani M, Aalipour M, Heydari E . Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy. Pharmacol Res. 2022; 184:106418. DOI: 10.1016/j.phrs.2022.106418. View

Hu Y, Zhang X, Li Q, Chen Y . Auditing the Immunization Data Quality from Routine Reports in Shangyu District, East China. Int J Environ Res Public Health. 2016; 13(11). PMC: 5129368. DOI: 10.3390/ijerph13111158. View

10.

Hu Z, Yang C, Guo S, Li Y, Li Y . LINC01615 activates ZEB2 through competitively binding with miR-3653-3p to promote the carcinogenesis of colon cancer cells. Cell Cycle. 2021; 21(3):228-246. PMC: 8855844. DOI: 10.1080/15384101.2021.2015670. View

11.

Huang G, Zang H, Geng Y, Li Y . LncRNA FAM83A-AS1 aggravates the malignant development of esophageal cancer by binding to miR-495-3p. Eur Rev Med Pharmacol Sci. 2020; 24(18):9408-9415. DOI: 10.26355/eurrev_202009_23024. View

12.

Huang H, Yang C, Zhang Q, Zhuo T, Li X, Li N . Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression. Bioengineered. 2022; 13(3):4964-4977. PMC: 8973779. DOI: 10.1080/21655979.2022.2037871. View

13.

Iser I, Pereira M, Lenz G, Wink M . The Epithelial-to-Mesenchymal Transition-Like Process in Glioblastoma: An Updated Systematic Review and In Silico Investigation. Med Res Rev. 2016; 37(2):271-313. DOI: 10.1002/med.21408. View

14.

Ji D, Chen G, Liu X, Zhu J, Sun J, Zhang X . Identification of LINC01615 as potential metastasis-related long noncoding RNA in hepatocellular carcinoma. J Cell Physiol. 2018; 234(8):12964-12970. DOI: 10.1002/jcp.27963. View

15.

Jia J, Li H, Chu J, Sheng J, Wang C, Jia Z . LncRNA FAM83A-AS1 promotes ESCC progression by regulating miR-214/CDC25B axis. J Cancer. 2021; 12(4):1200-1211. PMC: 7797654. DOI: 10.7150/jca.54007. View

16.

Jiang X, Guan J, Xu Y, Ren H, Jiang J, Wudu M . Silencing of CASC8 inhibits non-small cell lung cancer cells function and promotes sensitivity to osimertinib via FOXM1. J Cancer. 2021; 12(2):387-396. PMC: 7739000. DOI: 10.7150/jca.47863. View

17.

Jiang X, Chen M, Du J, Bi H, Guo X, Yang C . LncRNA-AC068228.1 Is a Novel Prognostic Biomarker That Promotes Malignant Phenotypes in Lung Adenocarcinoma. Front Oncol. 2022; 12:856655. PMC: 8904746. DOI: 10.3389/fonc.2022.856655. View

18.

Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3):178-96. PMC: 4240281. DOI: 10.1038/nrm3758. View

19.

Li Z, Wu Y, Zhang C, Dai S, Wei S, Zhao R . LncRNA SNHG5 Suppresses Cell Migration and Invasion of Human Lung Adenocarcinoma via Regulation of Epithelial-Mesenchymal Transition. J Oncol. 2023; 2023:3335959. PMC: 9879674. DOI: 10.1155/2023/3335959. View

20.

Liu W, Wan Q, Zhou E, He P, Tang L . LncRNA LINC01833 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Patients with Lung Adenocarcinoma by Integrated Bioinformatics Analysis. J Oncol. 2023; 2023:3965198. PMC: 9897928. DOI: 10.1155/2023/3965198. View